BioCatalystWatch
MESOWorkspace / MESO / OverviewCompany library
Price
Market cap
Next catalystQ4 CY2027 interim analysis, when the first 102 patients reach Day 28RYONCIL + ruxolitinib — adult Grade III/IV SR-aGvHD · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

RYONCIL (remestemcel-L-rknd)RYONCIL + ruxolitinib — adult Grade III/IV SR-aGvHD

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

RYONCIL (remestemcel-L-rknd)RYONCIL + ruxolitinib — adult Grade III/IV SR-aGvHD

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

RYONCIL (remestemcel-L-rknd)

PreINDP1P2P3FilingApproved
REVASCOR (rexlemestrocel-L)

PreINDP1P2P3FilingApproved
MOG-CAR-MSC

PreINDP1P2P3FilingApproved
CD19-CAR-MSC

CD19

CD44v6-OV-MSC

CD44v6 × PD-L1

OV/IL12/PDL1

PD-L1

PreINDP1P2P3FilingApproved
CAR-MSC-CCN1

PreINDP1P2P3FilingApproved
ECAD-CAR-MSC

E-cadherin

AMPA-CAR-MSC

PreINDP1P2P3FilingApproved

Partner / License out

Cell therapy

PreINDP1P2P3FilingApproved

Cell therapy

Cell therapy

Approved / commercial

History / paused

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MESO PR & News

MESO SEC archive